drugset / Trial / NCT07016633
To Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of IMM-H014 in Patients With MASH
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the tolerability, pharmacokinetics, and pharmacodynamics of consecutive Multiple treatment for 12 weeks（84 Days） in Adult Patients with Metabolic Dysfunction-Associated Steatohepatitis. Participants will receive either IMM-H014 or placebo.
Timeline
- Start
- 2025-06-10
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMM-H014 | Unknown | 125 mg | Oral |
| Subject | IMM-H014 | Unknown | 225 mg | Oral |
| Subject | IMM-H014 | Unknown | 325 mg | Oral |
| Subject | IMM-H014 | Unknown | 400 mg | Oral |